GlassScriptPhysician profile
Mirsen Lekovic
NPI 1811285174
$6,099.87
in general payments reported to CMS, 2019-2025
34 companies · $840 in 2025
The $840 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.77 · 2020: $14.85 · 2021: $2,017 · 2022: $981 · 2023: $1,189 · 2024: $1,045 · 2025: $840.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,074.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,073.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,362.53 | 2021 | |
| Novo Nordisk INC | $672.74 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $507.14 | 2019-2025 | |
| Lilly USA, LLC | $443.60 | 2021-2025 | Mounjaro, Jardiance, Omvoh |
| Abbvie INC. | $438.98 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.23 | 2021-2025 | Xifaxan, Trulance |
| Amgen INC. | $389.06 | 2021-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $236.93 | 2022-2025 | |
| Glaxosmithkline, LLC. | $174.07 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $151.25 | 2021-2025 | Gattex, Entyvio |
| Daiichi Sankyo INC. | $122.53 | 2022-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $116.99 | 2022-2025 | Belsomra, Dificid, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.19 | 2021-2023 | Ofev |
| Nestle Healthcare Nutrition INC. | $101.69 | 2021-2022 | |
| Ardelyx, INC. | $95.21 | 2024-2025 | Ibsrela |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $90.18 | 2023-2025 | Sucraid |
| Astrazeneca Pharmaceuticals LP | $84.75 | 2021-2025 | Airsupra |
| Boston Scientific Corporation | $66.21 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $61.97 | 2022 | |
| Phathom Pharmaceuticals, INC. | $56.54 | 2024-2025 | Voquezna |
| Abiomed | $54.71 | 2023 | Impella |
| Philips North America LLC | $53.36 | 2022-2024 | (Ck7) Extended Holter |
| Astellas Pharma US INC | $51.79 | 2023-2024 | Veozah, Myrbetriq |
| Abbott Laboratories | $34.82 | 2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $32.24 | 2023 | Quviviq |
| Redhill Biopharma INC. | $31.53 | 2021 | |
| Sumitomo Pharma America, INC. | $24.60 | 2024 | Gemtesa |
| Janssen Biotech, INC. | $23.80 | 2024 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $18.90 | 2024 | Dupixent |
| Sandoz INC. | $15.08 | 2023 | Hyrimoz |
| Optinose US, INC. | $14.85 | 2020 | |
| Corcept Therapeutics | $13.91 | 2025 | Korlym |
| Inari Medical, INC. | $13.27 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Novartis Pharmaceuticals Corporation | $13.22 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirsen Lekovic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.